Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q2 2017 call → NOWe need to determine if management conveys that the business is currently doing is visibly outgrowing the company's own size. The question asks: does management describe current activity, demand, or commitments arriving at a scale that is large relative to how small the company still is, so that reported results look like early portion of something meaningfully bigger? Answer YES if management's own words convey that the company is small and what is happening now is disproportionately large compared with that smallness. In the transcript, management discusses challenges with supply, production delays, and recapture. They talk about restoring supply, clearing back orders, and building safety stock. They mention that they are prioritizing investments to restore full product supply. They also mention that they have a strong pipeline and new products like Persona Partial Knee, etc. But do they convey that the company is small relative to the opportunity? They talk about growth in Asia-Pacific, but that's not necessarily about being small. They mention that they have a lot of work ahead, but they don't explicitly say that the current business is disproportionately large relative to their size. They talk about recapturing lost business and going on offense, but that's about recovering from issues, not about being small. They also mention that they have a strong portfolio and are confident in long-term growth. However, the question is about whether the current activity, demand, or commitments are large relative to the company's small size. The company is a large medical device company (Zimmer Biomet) with billions in revenue. They are not small. They are a leading participant. The transcript does not convey that they are small relative to what is happening. They talk about challenges and recovery, but not about being a small company with disproportionately large opportunities. They mention that they have a strong pipeline and new products, but that's typical. They also mention that they are investing in manufacturing and quality enhancements. There is no statement that the current business is outgrowing their size. They are a large company. So the answer is NO. The question also says: "Answer NO if the company is large relative to what it describes, or already a leading participant with no meaningful disproportion ahead of it." That fits. So NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.